- Zacks•last month
Mylan N.V. (MYL) and Biocon Ltd. announced that the FDA has accepted their biologics license application for a biosimilar version of Amgen's (AMGN) Neulasta (pegfilgrastim) - MYL-1401H.
- PR Newswire•last month
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Pegfilgrastim for Review
HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Feb. 16, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration (FDA) has accepted Mylan's Biologics License Application (BLA) for MYL-1401H, a proposed biosimilar to Neulasta® (pegfilgrastim), for filing through the 351(k) pathway.
- Capital Cube•2 months ago
Categories: Yahoo Finance Get free summary analysis Biocon Ltd. reports financial results for the quarter ended December 31, 2016. Highlights Summary numbers: Revenues of INR 10225 million, Net Earnings of INR 1713 million. Gross margins widened from 35.56% to 41.86% compared to the same period last year, operating (EBITDA) margins now 25.53% from 17.31%. Earnings growth from operating ... Read more (Read more...)
BIOCON.BO : Summary for BIOCON LTD. - Yahoo Finance
Biocon Limited (BIOCON.BO)
BSE - BSE Real Time Price. Currency in INR
Add to watchlist
|Day's Range||1,128.35 - 1,146.55|
|52 Week Range||463.30 - 1,150.00|
|PE Ratio (TTM)||25.49|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|